Compare · ABT vs BLCO
ABT vs BLCO
Side-by-side comparison of Abbott Laboratories (ABT) and Bausch + Lomb Corporation (BLCO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ABT focuses on Biotechnology: Pharmaceutical Preparations, while BLCO focuses on Ophthalmic Goods.
- ABT is the larger of the two at $191.31B, about 25.0x BLCO ($7.64B).
- ABT has been more active in the news (14 items in the past 4 weeks vs 9 for BLCO).
- ABT has more recent analyst coverage (25 ratings vs 22 for BLCO).
- Company
- Abbott Laboratories
- Bausch + Lomb Corporation
- Price
- $109.88-0.52%
- -
- Market cap
- $191.31B
- $7.64B
- 1M return
- +8.47%
- -
- 1Y return
- -13.02%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Ophthalmic Goods
- Exchange
- NYSE
- NYSE
- IPO
- 2022
- News (4w)
- 14
- 9
- Recent ratings
- 25
- 22
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Latest ABT
- New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season
- EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)
- SEC Form 10-Q filed by Abbott Laboratories
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
- Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
- Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
Latest BLCO
- SVP, Controller and CAO Munsch Frederick exercised 112,015 shares at a strike of $17.99 and sold $2,294,067 worth of shares (112,015 units at $20.48) (SEC Form 4)
- Director Robertson Russel C was granted 1,256 shares, increasing direct ownership by 1% to 95,516 units (SEC Form 4)
- Director Paulson John was granted 1,125 shares, increasing direct ownership by 1% to 90,948 units (SEC Form 4)
- Director Alfonso Eduardo was granted 1,125 shares, increasing direct ownership by 4% to 32,197 units (SEC Form 4)
- Bausch + Lomb downgraded by H.C. Wainwright with a new price target
- SEC Form 8-K filed by Bausch + Lomb Corporation
- SEC Form 10-Q filed by Bausch + Lomb Corporation
- SEC Form 8-K filed by Bausch + Lomb Corporation
- Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
- SEC Form 8-K filed by Bausch + Lomb Corporation